MCL1 and acute myeloid leukemia: Based on our results, an umbrella trial utilizing BCL2, MCL1/BCL2, and BFL1/MCL1 inhibitors based on BFSigs seems to be an ideal design to maximize the success of apoptosis inducing agents in AML [78].